Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Shanghai - Delayed Quote CNY

HOB Biotech Group Corp.,Ltd (688656.SS)

Compare
96.30
-1.92
(-1.95%)
At close: April 3 at 3:00:03 PM GMT+8
Loading Chart for 688656.SS
  • Previous Close 98.22
  • Open 97.00
  • Bid 96.30 x --
  • Ask 96.80 x --
  • Day's Range 95.18 - 99.60
  • 52 Week Range 19.47 - 165.21
  • Volume 745,804
  • Avg. Volume 891,421
  • Market Cap (intraday) 6.073B
  • Beta (5Y Monthly) -0.63
  • PE Ratio (TTM) 166.03
  • EPS (TTM) 0.58
  • Earnings Date --
  • Forward Dividend & Yield 0.40 (0.42%)
  • Ex-Dividend Date Jun 14, 2024
  • 1y Target Est --

HOB Biotech Group Corp.,Ltd. operates as a in vitro diagnostic company in China and internationally. It provides diagnostic tools, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immuno assays to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. The company was founded in 2009 and is based in Suzhou, China.

www.hobiotech.com

529

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 688656.SS

View More

Performance Overview: 688656.SS

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

688656.SS
0.84%
SSE Composite Index (000001.SS)
0.29%

1-Year Return

688656.SS
274.02%
SSE Composite Index (000001.SS)
8.89%

3-Year Return

688656.SS
142.77%
SSE Composite Index (000001.SS)
1.81%

5-Year Return

688656.SS
47.02%
SSE Composite Index (000001.SS)
20.91%

Compare To: 688656.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688656.SS

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    6.07B

  • Enterprise Value

    6.07B

  • Trailing P/E

    166.03

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    15.19

  • Price/Book (mrq)

    7.48

  • Enterprise Value/Revenue

    15.08

  • Enterprise Value/EBITDA

    68.25

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.15%

  • Return on Assets (ttm)

    2.79%

  • Return on Equity (ttm)

    4.54%

  • Revenue (ttm)

    402.34M

  • Net Income Avi to Common (ttm)

    36.8M

  • Diluted EPS (ttm)

    0.58

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    121.63M

  • Total Debt/Equity (mrq)

    14.25%

  • Levered Free Cash Flow (ttm)

    -48.66M

Research Analysis: 688656.SS

View More

Company Insights: 688656.SS

Research Reports: 688656.SS

View More

People Also Watch